TY - JOUR
T1 - Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
AU - Griguolo, Gaia
AU - Dieci, Maria Vittoria
AU - Paré, Laia
AU - Miglietta, Federica
AU - Generali, Daniele Giulio
AU - Frassoldati, Antonio
AU - Cavanna, Luigi
AU - Bisagni, Giancarlo
AU - Piacentini, Federico
AU - Tagliafico, Enrico
AU - Cagossi, Katia
AU - Ficarra, Guido
AU - Prat, Aleix
AU - Conte, Pierfranco
AU - Guarneri, Valentina
N1 - Funding Information: We thank the patients that participated in the LETLOB trial, their families and all the investigators involved in the trial. The LETLOB trial was sponsored and funded by GlaxoSmithKline. Moreover, we acknowledge the following fundings: Istituto Oncologico Veneto project L02P38; University of Padova project 60A07-7808/13; Istituto Oncologico Veneto projects L04P11 (to V.G.), L02P03 (to M.V.D.), L04P25 (to M. V.D.), L03P07 (to P.F.C.), L05P07 (to P.F.C.); DOR funding from the University of Padova —Department of Surgery, Oncology and Gastroenterology BIRD 2019 (to V.G., M.V.D., P.F.C.) and BIRD 2020 (to V.G., M.V.D., G.G.). Publisher Copyright: © 2021, The Author(s).
M1 - 12
PY - 2021/12
Y1 - 2021/12
N2 - Little is known regarding the interaction between immune microenvironment and tumor biology in hormone receptor (HR)+/HER2− breast cancer (BC). We here assess pretreatment gene-expression data from 66 HR+/HER2− early BCs from the LETLOB trial and show that non-luminal tumors (HER2-enriched, Basal-like) present higher tumor-infiltrating lymphocyte levels than luminal tumors. Moreover, significant differences in immune infiltrate composition, assessed by CIBERSORT, were observed: non-luminal tumors showed a more proinflammatory antitumor immune infiltrate composition than luminal ones.
AB - Little is known regarding the interaction between immune microenvironment and tumor biology in hormone receptor (HR)+/HER2− breast cancer (BC). We here assess pretreatment gene-expression data from 66 HR+/HER2− early BCs from the LETLOB trial and show that non-luminal tumors (HER2-enriched, Basal-like) present higher tumor-infiltrating lymphocyte levels than luminal tumors. Moreover, significant differences in immune infiltrate composition, assessed by CIBERSORT, were observed: non-luminal tumors showed a more proinflammatory antitumor immune infiltrate composition than luminal ones.
U2 - 10.1038/s41523-021-00223-x
DO - 10.1038/s41523-021-00223-x
M3 - Article
SN - 2374-4677
VL - 7
JO - npj Breast Cancer
JF - npj Breast Cancer
IS - 1
M1 - 12
ER -